Page last updated: 2024-12-08
nsc 710305
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Phortress: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9804228 |
CHEMBL ID | 1793884 |
MeSH ID | M0414710 |
Synonyms (18)
Synonym |
---|
nsc-710305 |
phortress |
CHEMBL1793884 |
nsc 710305 |
328087-38-3 |
(2s)-2,6-diamino-n-[4-(5-fluoro-2-benzothiazolyl)-2-methylphenyl]hexanamide dihydrochloride |
AKOS024458457 |
gs-1302 , |
5f-df-203-l-lysinamide dihydrochloride |
(2s)-2,6-diamino-n-(4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methyl-phenyl)hexanamide hydrochloride |
AXR52N9SMF , |
hexanamide, 2,6-diamino-n-(4-(5-fluoro-2-benzothiazolyl)-2-methylphenyl)-, hydrochloride (1:2), (2s)- |
unii-axr52n9smf |
328087-38-3 (hcl) |
(s)-2,6-diamino-n-(4-(5-fluorobenzo[d]thiazol-2-yl)-2-methylphenyl)hexanamide dihydrochloride |
CS-0025314 |
(2s)-2,6-diamino-n-[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]hexanamide;dihydrochloride |
HY-103223 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate." | ( Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. Hutchinson, I; Jennings, SA; Stevens, MF; Vishnuvajjala, BR; Westwell, AD, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |